Diadexus, Inc. announced unaudited financial results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported total revenue of $3.5 million, compared to $6.0 million for the fourth quarter of 2014. This decrease was primarily attributable to a reduction in service revenues as the company completed an agreement with GSK in the fourth quarter of 2014. Net loss was $1.5 million, or $0.37 per basic and diluted share, compared to a net loss of $2.3 million, or $0.62 per basic and diluted share, in the fourth quarter of 2014. Loss from operations was $993,000 against $1,927,000 a year ago. Loss before income tax was $1,521,000 against $2,305,000 a year ago.

For the full year, the company reported total revenues of $18.1 million, compared to $26.4 million for the year ended December 31, 2014. This decrease was primarily attributable to a reduction in service revenues as Diadexus completed a $5 million agreement with GSK in the fourth quarter of 2014. Net loss was $7.2 million, or $1.83 per basic and diluted share, compared to a net loss of $8.5 million, or $2.30 per basic and diluted share, for the year ended December 31, 2014. Loss from operations was $5,250,000 against $6,982,000 a year ago. Loss before income tax was $7,155,000 against $8,452,000 a year ago. This 6% increase in revenue was driven by services they provided under a 2014 agreement with GSK. Cash used in operating activities decreased to $5.5 million for the year ended December 31, 2015, compared to $7.0 million for the year ended December 31, 2014.